Press release |

Approved as part of a novel shorter treatment regimen, the new drug pretomanid could be a lifesaver for people with XDR-TB, but MSF warns it must be made affordable to make a real difference.

Read more
Photograph by Jan-Joseph Stok

What good is a breakthrough medicine if the people who need it can't afford it?